“…One of the challenges related to employing PB2 as anticancer agents is the poor bioavailability, which might associate with its low water solubility, instability under the physicochemical conditions of the gastrointestinal tract, as well as the difficulty of cell membrane diffusion 48‐51 . However, some promising approaches have been proposed to enhance the bioavailability of polyphenol, mainly including (a) the structural modification, such as methylation, hydroxylethylation and amino acid substitution, to decrease the physiochemical degradation and enhance the intestinal absorption rate, 52,53 (b) bioactive carrier systems, such as phytosome/liposome vehicles, solid lipid nanoparticles, microencapsulation and nano‐graphene oxide systems, to deliver the agents to the target sites with minimal side effects, 48,54 (c) co‐administration with other dietary components, such as intestinal absorption enhancers and dietary lipids, to improve the permeability of intestinal epithelial cells, delay gastric empty and prolong bowel transit time 54,55 . We will conduct clinical studies to further investigate whether PB2 assisted with nanomaterials could facilitate its bioavailability, and thus improve its therapeutic effects on osteosarcoma patients in the future.…”